Biomarkers /
TACC1
Overview
TACC1 is altered in 0.08% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, bladder urothelial carcinoma, dysembryoplastic neuroepithelial tumor, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in TACC1 are TACC1-FGFR1 Fusion (0.02%), TACC1-CYLD Fusion (0.00%), TACC1-INSR Fusion (0.00%), and TACC1-WHSC1L1 Fusion (0.00%) [3].
Clinical Trials
Significance of TACC1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.